Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008744 | 0.79 | KCNH2 (0.47) | ADRB2ADRB1ADRB3KCNH2KDM4E | |
| SCHEMBL8214793 | 0.73 | KCNH2 (0.49) | ADRB2ADRB1ADRB3KCNH2SLC6A2 | |
| Hydrochloric Acid SCHEMBL8217971 | 0.73 | KCNH2 (0.48) | ADRB2ADRB1ADRB3KCNH2SLC6A2 | |
| SCHEMBL7699543 | 0.71 | KCNH2 (0.58) | ADRB2ADRB1ADRB3KCNH2KDM4E | |
| Hydrochloric Acid SCHEMBL7701677 | 0.70 | KCNH2 (0.57) | ADRB2ADRB1ADRB3KCNH2 | |
| SCHEMBL6140360 | 0.70 | KCNH2 (0.50) | KCNH2KDM4E | |
| SCHEMBL9654030 | 0.68 | ADRB1 (0.82) | ADRB2ADRB1ADRB3KCNH2SLC6A2 | |
| SCHEMBL9386639 | 0.68 | KDM4E (0.59) | ADRB2ADRB1ADRB3KCNH2SLC6A2 | |
| SCHEMBL9384685 | 0.68 | ADRB2 (0.57) | ADRB2ADRB1ADRB3KCNH2SLC6A2 | |
| SCHEMBL17143188 | 0.67 | LMNA (0.58) | ADRB2ADRB1ADRB3KCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362062-B2 | Pharmaceutical compositions with improved dissolution | MCNEIL-PPC, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2339328-A2 | Pharmaceutical co-crystal compositions of celecoxib | Transform Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20060134198-A1 | Pharmaceutical compositions with improved dissolution | JOHNSON & JOHNSON CONSUMER INC. | 2006-06-22 | — | — | US | disclosed |
| US-20060052432-A1 | Pharmaceutical compositions with improved dissolution | TRANSFORM PHARMACEUTICALS, INC. | 2006-03-09 | — | — | US | disclosed |
| US-20050025791-A1 | Pharmaceutical compositions with improved dissolution | TRANSFORM PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| US-20030100595-A1 | Oral dosage form of a sulfonamide prodrug | PHARMACIA CORPORATION | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050025791-A1 | Pharmaceutical compositions with improved dissolution | ABCG2, SI, SLC10A2 | ADRB2 2605/4885ADRB1 3031/4885ADRB3 2061/4885 |
| US-20030100595-A1 | Oral dosage form of a sulfonamide prodrug | PTGS2, PTGES2, SI | ADRB2 4254/4885ADRB1 4765/4885ADRB3 4816/4885 |
| US-20060052432-A1 | Pharmaceutical compositions with improved dissolution | ABCG2, SI, SLC10A2 | ADRB2 2898/4885ADRB1 3177/4885ADRB3 2349/4885 |
| US-20060134198-A1 | Pharmaceutical compositions with improved dissolution | ABCG2, SI, SLC10A2 | ADRB2 2898/4885ADRB1 3177/4885ADRB3 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.